Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bemiparin in Recurrent Implantation Failure
NCT02607319Phase 4Completed
- Sponsor
- American University of Beirut Medical Center
- Start
- Nov 2015
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of bemiparin in Recurrent Implantation Failure (RIF) (2 arms), sponsored by American University of Beirut Medical Center. Primary endpoint: Implantation rate. Started Nov 2015; status: completed.
02
Drugs
bemiparin
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on NCT02607319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607319.